Title: Management of hepatitis B co-infection in human immunodeficiency virus infected subjects
Authors: Lessells R, Leen CLS.
Journal: Eur J Clin Micro ID,23(5):366-374 (2004)
Journal Impact Factor (I.F.): 2.631
The human immunodeficiency virus (HIV) and
the hepatitis B virus share common routes of transmission,
and hence, coinfection with these two viruses is common.
Chronic hepatitis B does not influence the progression of
HIV disease or the response to highly active antiretroviral
therapy. It is clear, however, that HIV infection does
impact the course of hepatitis B, as higher rates of chronic
carriage, lower seroconversion rates, and accelerated
progression towards cirrhosis have been observed. Vaccination
against hepatitis B is less effective in HIV-infected
Coinfected subjects have a poor response to
interferon therapy. Lamivudine is more effective in
coinfected subjects but must not be used as monotherapy
because of the risk of resistance developing. Combination
therapy with lamivudine and tenofovir has shown promise
and is currently being investigated in clinical trials, while
new drugs and other combinations are in development.
Citation: Lessells R, Leen CLS. Management of hepatitis B co-infection in human immunodeficiency virus infected subjects Eur J Clin Micro ID,23(5):366-374 (2004).